NIAID selects Tonix’s COVID-19 vaccine candidate TNX-1800 for inclusion in Project Nextgen trials
Nov. 3, 2023
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19.
